| UHC UMR Medical and Drug | Maximum Dosage and Frequency – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Mechanical Stretching Devices – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Minimally Invasive Procedures for Gastric and Esophageal Diseases - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Nerve Graft to Restore Erectile Function During Radical Prostatectomy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Neurophysiologic Testing and Monitoring – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Ocrevus® (Ocrelizumab) and Ocrevus Zunovo® (Ocrelizumab and Hyaluronidase-Ocsq) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Office-Based Procedures – Site of Service – Commercial and Individual Exchange Medical Policy | 2026-01-01 |